IDEAYA Biosciences
IDYA
36.26
-0.37
-1.01%
IDEAYA Biosciences
US · IDYA
#2357 by market cap
Listed 2019
36.26
-0.37
-1.01%
Live - 5344 symbols - heartbeat 345s ago
· 2026-10-08 08:24
Pre-market
37.50
+3.42%
After-hours
36.26
0.00%
- Market cap
- 3.50B
- P/E (TTM)i
- -18.89
- P/Bi
- 2.92
- EPSi
- -1.28
- Div yieldi
- 0.00%
- 52W posi
- 61%
Reader sentiment
Are you bullish or bearish on IDYA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 23.75, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +3,024.43% YoY
Margins
- Operating margin
- -72.84%
- Net margin
- -51.99%
Key ratios & quality
- Altman Z-Scorei
- 23.75
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 19.54M | 27.94M | 50.93M | 23.39M | 7.00M | 218.71M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 4.67M | 9.95M | 15.18M | 20.05M | 23.90M | 28.31M | 39.30M | 63.32M |
| Research & development | 31.75M | 34.32M | 39.70M | 58.16M | 89.54M | 129.51M | 294.67M | 314.70M |
| Operating profit | -36.42M | -44.27M | -35.34M | -50.27M | -62.50M | -134.43M | -326.98M | -159.31M |
| Pretax profit | -34.35M | -41.98M | -34.50M | -49.76M | -58.66M | -112.96M | -274.48M | -113.70M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -34.35M | -41.98M | -34.50M | -49.76M | -58.66M | -112.96M | -274.48M | -113.70M |
| Basic EPS | -2 | -3 | -1 | -1 | -1 | -2 | -3 | -1 |
| Diluted EPS | -2.41 | -3.36 | -1.40 | -1.41 | -1.42 | -1.96 | -3.36 | -1.28 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 207.83M | 10.88M | 6.56M | 8.86M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 13.50M | 14.58M | 16.39M | 18.85M | 19.38M | 22.46M |
| Research & development | 70.89M | 74.23M | 82.99M | 86.60M | 95.73M | 108.69M |
| Operating profit | -84.39M | -88.81M | 108.45M | -94.57M | -108.54M | -122.29M |
| Pretax profit | -72.18M | -77.49M | 119.24M | -83.27M | -98.54M | -112.45M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -72.18M | -77.49M | 119.24M | -83.27M | -98.54M | -112.45M |
| Basic EPS | -1 | -1 | 1 | -1 | -1 | -1 |
| Diluted EPS | -0.82 | -0.88 | 1.33 | -0.94 | -1.11 | -1.22 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 90.67M | 101.65M | 288.61M | 251.00M | 370.45M | 532.63M | 689.71M | 666.73M |
| Cash & ST investments | 89.96M | 98.96M | 283.59M | 246.77M | 364.83M | 525.11M | 676.32M | 639.39M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 96.54M | 113.00M | 298.27M | 381.35M | 387.97M | 649.32M | 1.12B | 1.11B |
| Total current liabilities | 5.41M | 6.94M | 38.64M | 45.16M | 31.72M | 27.10M | 46.07M | 58.82M |
| Short-term debt | -- | 1.15M | 1.54M | 1.70M | 1.87M | 1.75M | 298.00K | 339.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 145,489,000.00 | 12,601,000.00 | 99,995,000.00 | 79,833,000.00 | 38,514,000.00 | 28,226,000.00 | 64,944,000.00 | 86,390,000.00 |
| Total equity | -48.95M | 100.40M | 198.27M | 301.51M | 349.46M | 621.09M | 1.06B | 1.02B |
| Retained earnings | -50.52M | -92.49M | -126.99M | -176.75M | -235.40M | -348.36M | -622.84M | -736.54M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 707.87M | 685.60M | 802.66M | 666.73M | 696.11M | 864.03M |
| Cash & ST investments | 692.51M | 669.74M | 786.89M | 639.39M | 671.20M | 828.96M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.10B | 1.04B | 1.19B | 1.11B | 1.03B | 1.31B |
| Total current liabilities | 50.85M | 55.34M | 64.51M | 58.82M | 64.83M | 82.68M |
| Short-term debt | 308.00K | 318.00K | 328.00K | 339.00K | 350.00K | 1.19M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 76,506,000.00 | 81,617,000.00 | 93,102,000.00 | 86,390,000.00 | 93,081,000.00 | 110,794,000.00 |
| Total equity | 1.02B | 959.65M | 1.09B | 1.02B | 937.27M | 1.20B |
| Retained earnings | -695.02M | -772.51M | -653.27M | -736.54M | -835.08M | -947.53M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -27.62M | -39.31M | 55.46M | -55.78M | -87.18M | -115.22M | -247.58M | -71.10M |
| Depreciation & amortization | 886.00K | 1.25M | 1.38M | 3.03M | 3.52M | 4.01M | 3.83M | 4.59M |
| Free cash flow | -29.33M | -40.67M | 54.97M | -58.42M | -90.62M | -117.59M | -251.44M | -73.47M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 50.32M | 127.23M | 143.25M | 94.96M | 309.76M | 654.23M | 24.86M |
| Ending cash balance | 20.61M | 34.17M | 72.14M | 92.15M | 68.74M | 157.78M | 85.18M | 113.84M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -60.34M | -62.47M | 142.21M | -90.50M | -75.17M | -88.21M |
| Depreciation & amortization | 1.13M | 1.23M | 1.03M | 1.20M | 1.14M | 1.12M |
| Free cash flow | -61.67M | -63.14M | 142.17M | -90.83M | -76.14M | -89.08M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 25.01M | -25.00K | -83.00K | -46.00K | -9.00K | 216.44M |
| Ending cash balance | 130.80M | 115.45M | 299.73M | 113.84M | 158.80M | 273.87M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -163.16 | -23.10 | -19.91 | -18.02 | -23.28 | -32.67 | -10.92 |
| ROA %i | -60.37 | -40.06 | -16.77 | -14.64 | -15.25 | -21.78 | -30.95 | -10.18 |
| ROIC %i | -- | -149.11 | -22.64 | -19.65 | -18.95 | -27.52 | -38.42 | -14.96 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -49.49 | -23.40 | -20.96 |
| EBIT margin %i | -- | -- | -180.90 | -179.91 | -122.72 | -574.85 | -4,671.07 | -72.84 |
| FCF / sales %i | -- | -- | 281.35 | -- | -- | -- | -- | -- |
| Current ratioi | 16.75 | 14.65 | 7.47 | 5.56 | 11.68 | 19.65 | 14.97 | 11.34 |
| Quick ratioi | 16.62 | 14.26 | 7.39 | 5.49 | 11.51 | 19.38 | 14.68 | 10.97 |
| Debt / assetsi | 0.00 | 5.99 | 2.25 | 1.36 | 0.90 | 0.44 | 1.71 | 2.52 |
| LT debt / equityi | -- | 5.60 | 2.61 | 1.15 | 0.46 | 0.18 | 1.78 | 2.70 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | 6.17 | -36.96 | 62.54 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -31.11 | -35.09 | -14.15 | -10.92 | -14.28 | -16.22 |
| ROA %i | -29.56 | -32.93 | -13.26 | -10.18 | -13.15 | -14.89 |
| ROIC %i | -36.03 | -40.03 | -18.02 | -14.96 | -18.20 | -19.59 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -5,147.81 | -5,488.94 | -97.23 | -72.84 | -81.44 | -92.66 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 13.92 | 12.39 | 12.44 | 11.34 | 10.74 | 10.45 |
| Quick ratioi | 13.62 | 12.10 | 12.20 | 10.97 | 10.45 | 10.21 |
| Debt / assetsi | 2.36 | 2.55 | 2.30 | 2.52 | 2.78 | 2.24 |
| LT debt / equityi | 2.51 | 2.74 | 2.46 | 2.70 | 3.01 | 2.35 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Research and development for oncology-focused precision medicine100.00%
Quote time 2026-10-08 08:24:42 · For reference only, not investment advice and not tailored to your situation.